BioMarin Pharmaceutical Inc. (BMRN)
|52 Week Range||70.73-97.76|
|1y Target Est||-|
|DCF Unlevered||BMRN DCF ->|
|DCF Levered||BMRN LDCF ->|
|Debt / Equity||36.43%||Neutral|
Upgrades & Downgrades
Latest BMRN news
BioMarin Pharmaceutical: Leader In Rare Disease Innovation
2 October 2022
BioMarin Pharmaceutical's revenue was $533.8 million in Q2 2022, up 6.4% year-on-year. The company's net income has been growing at a substantial pace in recent quarters, helping to keep BioMarin Phar...
BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy
30 September 2022
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to t...
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
22 September 2022
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU
25 August 2022
BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
4 August 2022
Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q2 2022 Results - Earnings Call Transcript
4 August 2022
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Traci McCarty - Vice President of Investor Relations J.J. Bienaime - Chairma...
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
3 August 2022
BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
These eight health-care stocks can keep you invested in the market with less worry
2 August 2022
You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.
BioMarin: More Growth
21 July 2022
The recent Japan approval of Voxzogo for achondroplasia would generate a leaping sales growth in the coming quarters. BioMarin is also expanding Voxzogo's label for younger kids afflicted by achondrop...
BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, Aug...
20 July 2022
SAN RAFAEL, Calif. , July 20, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a...